NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Phoenix Tree Holdings Limited (NYSE DNK), Groupon, Inc. (NASDAQ: GRPN), and SCWorx Corp. (NADSAQ: WORX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Phoenix Tree Holdings Limited (NYSE: DNK)
Class Period: Securities purchased pursuant and/or traceable to the Company’s January 22, 2020 initial public offering (the “IPO” or “Offering”).
Lead Plaintiff Deadline: June 26, 2020
Phoenix Tree, a holding company that leases and manages apartments in China, held its initial public offering (“IPO”) for its American Depositary Shares (“ADS”) on January 22, 2020, in which it sold 9.6 million ADS at $13.50 per share.
The complaint, filed on April 24, 2020, alleges that the IPO materials misrepresented and/or failed to disclose the nature and level of renter complaints that Phoenix Tree had received before and as of the IPO, plus the Company’s exposure to significant adverse developments resulting from the onset of COVID-19 in China.
The company’s ADS are presently trading around $6.59 each, or nearly half of their IPO price.
For more information on the Phoenix Tree Holdings class action go to: https://bespc.com/DNK
Groupon, Inc. (NASDAQ: GRPN)
Class Period: November 4, 2019 to February 28, 2020
Lead Plaintiff Deadline: June 29, 2020
On February 18, 2020, Groupon reported fourth quarter 2019 sales of $612.3 million, a nearly 23% decline over the prior year period. The Company’s adjusted EBITDA for fiscal 2019 was reported at $227.2 million, a significant miss from its November 2019 forecast of $270 million. Groupon also announced a “transformational plan to exit Goods” in North America by the third quarter and globally by the end of the year.
On this news, the Company’s share price fell $1.35, or over 44%, to close at $1.70 per share on February 19, 2020.
The complaint, filed on April 28, 2020, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the Company was experiencing fewer customer engagements in its Goods category; (2) that Groupon relied on its Goods category to drive its sales, especially during the holiday season; (3) that, as a result of the foregoing, the Company was likely to experience reduced sales; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
For more information on the Groupon class action go to: https://bespc.com/GRPN
SCWorx Corp. (NASDAQ: WORX)
Class Period: April 13, 2020 to April 17, 2020
Lead Plaintiff Deadline: June 29, 2020
On April 13, 2020, SCWorx announced that it had received a committed purchase order of two million COVID-19 rapid testing kits, “with provision for additional weekly orders of 2 million units for 23 weeks, valued at $35M per week.”
On this news, the Company’s share price increased by $9.77, to close at $12.02 per share on April 13, 2020.
On April 17, 2020, Hindenburg Research issued a report doubting the validity of the deal, calling it “completely bogus.” According to Hindenburg Research, the Covid-19 test supplier that SCWorx is buying from, Promedical, has a Chief Executive Officer “who formerly ran another business accused of defrauding its investors and customers” and “was also alleged to have falsified his medical credentials,” Promedical claimed to the FDA and regulators in Australia to be offering COVID-19 test kits manufactured by Wondfo, but “Wondfo put out a press release days ago stating that Promedical ‘fraudulently mispresented themselves’ as sellers of its Covid-19 tests and disavowed any relationship,” and the buyer that SCWorx claimed to have lined up does not appear to be “capable of handling hundreds of millions of dollars in orders.”
On this news, the Company’s share price fell $1.19, or more than 17%, over three consecutive trading sessions to close at $5.76 per share on April 21, 2020.
On April 22, 2020, the SEC halted trading of the Company’s stock. As of the filing of the complaint, trading remains halted.
The complaint, filed on April 29, 2020, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that SCWorx’s supplier for COVID-19 tests had previously misrepresented its operations; (2) that SCWorx’s buyer was a small company that was unlikely to adequately support the purported volume of orders for COVID-19 tests; (3) that, as a result, the Company’s purchase order for COVID-19 tests had been overstated or entirely fabricated; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
For more information on the SCWorx class action go to: https://bespc.com/WORX
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Bragar Eagel & Squire, P.C.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
© 2021 Canjex Publishing Ltd. All rights reserved.